Dr. Reddy's Laboratories (RDY) to Release Earnings on Tuesday

Key Points

• Dr. Reddy's will report Q4 25/26 results before the market opens on Tuesday, May 12, 2026 at 10:00 AM ET, with analysts forecasting $0.09 EPS and about $886.6 million in revenue.
• The stock trades around $13.25 with a market cap of $11.06 billion and a 52-week range of $12.77–$16.17; Wall Street's consensus is a Hold (average target $16.90) while Goldman Sachs recently downgraded the stock to Sell.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) will likely be posting its Q4 25/26 results before the market opens on Tuesday, May 12th. Analysts expect Dr. Reddy's Laboratories to post earnings of $0.09 per share and revenue of $886.5750 million for the quarter. Individuals may visit the the company's upcoming Q4 25/26 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 10:00 AM ET.

Dr. Reddy's Laboratories Price Performance

Shares of NYSE:RDY traded down $0.10 on Tuesday, hitting $13.25. The company had a trading volume of 70,381 shares, compared to its average volume of 2,140,822. The company has a current ratio of 1.88, a quick ratio of 1.38 and a debt-to-equity ratio of 0.03. Dr. Reddy's Laboratories has a 52-week low of $12.77 and a 52-week high of $16.17. The business has a 50 day moving average of $13.80 and a 200 day moving average of $13.86. The company has a market cap of $11.06 billion, a PE ratio of 17.19, a PEG ratio of 21.31 and a beta of 0.27.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. The Goldman Sachs Group downgraded Dr. Reddy's Laboratories from a "neutral" rating to a "sell" rating in a research report on Thursday, April 23rd. Weiss Ratings upgraded Dr. Reddy's Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $16.90.

Institutional Investors Weigh In On Dr. Reddy's Laboratories

A number of large investors have recently modified their holdings of RDY. Invesco Ltd. grew its stake in shares of Dr. Reddy's Laboratories by 7.6% in the second quarter. Invesco Ltd. now owns 253,342 shares of the company's stock valued at $3,808,000 after buying an additional 17,907 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Dr. Reddy's Laboratories by 71.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company's stock valued at $47,000 after purchasing an additional 1,294 shares in the last quarter. First Trust Advisors LP grew its holdings in Dr. Reddy's Laboratories by 23.3% during the 2nd quarter. First Trust Advisors LP now owns 65,652 shares of the company's stock valued at $987,000 after purchasing an additional 12,390 shares in the last quarter. Sei Investments Co. grew its holdings in Dr. Reddy's Laboratories by 37.3% during the 2nd quarter. Sei Investments Co. now owns 124,136 shares of the company's stock valued at $1,866,000 after purchasing an additional 33,747 shares in the last quarter. Finally, Quantinno Capital Management LP grew its holdings in Dr. Reddy's Laboratories by 92.6% during the 2nd quarter. Quantinno Capital Management LP now owns 235,044 shares of the company's stock valued at $3,533,000 after purchasing an additional 112,988 shares in the last quarter. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company's core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.